Antibody-Drug Conjugation at ChemPartner

ChemPartner has a top-tier Antibody-Drug Conjugation (ADC) team spanning multiple areas, including antibody development, design and synthesis of linker and payload, conjugation chemistry, as well as ADC analytical, efficacy, toxicology, and DMPK studies. Using state-of-the-art technologies, our scientists have been helping numerous clients design novel ADCs and solve technical challenges in their ADC development processes. Please click on the following posters for more details.

An Anti-Her2 Antibody-Drug Conjugate XDCE-1 for Targeted Cancer Therapy

A series of novel Matansinol-derived toxins was designed, synthesized and assessed for their suitability in developing anti-Her2 antibody-drug conjugates. Among all ADCs tested, one demonstrated high potency, low hepatotoxicity and desired PK profile.

Synergistic Efficacy of an Anti-TPBG mAb-MMAE and an Anti-PD1 mAb

A humanized anti-TPBG mAb was developed and conjugated with MMAE. The resulting ADC was then studied by co-administration with an anti-PD1 mAB in a mouse model, where significant synergistic tumor growth inhibition and enhanced disease control were observed.

Antibody-Toxin Conjugate with a Novel Linker-payload

We have established a robust and efficient way to conjugate novel linker-payload compounds to antibodies using a semi-automatic system. This process is suitable for generating ADC products of consistent high quality, such as purify, DAR and bioactivities.